Pasar al contenido principal

Resultados de investigación

Rights
Projectcode
Resultados totales (Incluyendo duplicados): 54623
Encontrada(s) 5463 página(s)
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/31694
Publicación Otros (Other)

Self-Efficacy in the Cannulation Technique for Intraosseous Access in Pediatric Cardiac Arrest Egg Versus Bone

Autoeficacia en la técnica de canulación para acceso intraóseo en paro cardíaco pediátrico: huevo versus hueso
  • Marquez-Hernandez, Veronica
  • Garrido-Molina, Jose-Miguel
  • Gutierrez-Puertas, Lorena
  • Garcia-Viola, Alba
  • Gutierrez-Puertas, Vanesa
  • Aguilera-Manrique, Gabriel
  • Rodriguez-Garcia, Carmen
Objectives: The use of intraosseous (IO) access is recommended in cardiac arrest when peripheral venous access is not accessible. Various methodologies exist that are used for teaching and learning about cannulation of the IO route both in education and in research. The purpose of the present study was to compare self-efficacy in the cannulation technique for IO access through different techniques. Methods: A randomized comparative study was conducted. A total of 118 nursing students participated. The participants were randomly distributed into 2 intervention groups: chicken bone and egg. A checklist was used for data collection to evaluate the IO cannulation technique in nursing students and another to analyze self-efficacy. Results: The average total score of self-efficacy for all participants was 8.84 (standard deviation (SD) = 0.98). No statistically significant differences were found when comparing the total self-efficacy score and the intervention group ( U = 1604.500; z = -0.733; P = 0.463). No statistically significant differences were found between both groups for the average total score of the procedure ( U = 6916.500; z = -0.939; P = 0.348). The egg group carried out the IO cannulation procedure in a significantly less amount of time (M = 126.88, SD = 82.18) than the chicken bone group (M = 183.77, SD = 108.28), finding statistically significant differences ( U = 4983.500; z = -5.326; P < 0.001). Conclusions: Using an egg to teach and learn about IO access could be considered a methodology that is equally effective as using a chicken bone, with the advantage of achieving IO access in a lesser amount of time., Yes
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/11951
Publicación Otros (Other)

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

  • Ponde, Noam
  • Bradbury, Ian
  • Lambertini, Matteo
  • Ewer, Michael
  • Campbell, Christine
  • Ameels, Helene
  • Zardavas, Dimitrios
  • Di-Cosimo, Serena
  • Baselga, José
  • Huober, Jens
  • Izquierdo, Miguel
  • Fumagalli, Debora
  • Bozovic-Spasojevic, Ivana
  • Maetens, Marion
  • Harbeck, Nadia
  • Pusztai, Lajos
  • Berghorn, Michael
  • Im, Young-Hyuck
  • Borrego, Manuel Ruiz
  • Chen, Dar-Ren
  • Rodeheffer, Richard
  • Piccart, Martine
  • Suter, Thomas
  • Azambuja, Evandro-de
Biomarkers of cardiac damages, such as troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP), may be useful as early predictors of cardiac dysfunction. The role of these biomarkers in patients receiving lapatinib and/or trastuzumab before anthracyclines is unknown. This study explores TnT and NT-proBNP as predictors of early cardiac toxicity in neoadjuvant breast cancer patients. This sub-study of the NEOALTTO trial tested if changes in the levels of TnT and NT-proBNP occurred after 2 weeks of anti-HER2 therapy (lapatinib, trastuzumab or their combination) alone and/or after 18 weeks of anti-HER2 therapy plus weekly paclitaxel. 173 and 172 were tested at all three timepoints for NT-proBNP and TnT, respectively. The incidence of biomarker elevation was overall low at all timepoints for all the three treatment arms. A total of 13 CEs in 11 patients occurred. Biomarker elevations in patients with CEs were very rare; only one patient with subsequent CE had a NT-proBNP elevation at baseline and at week 2. These results suggest that TnT and proBNP may not be useful as early predictors of cardiac toxicity in anthracycline-naïve patients receiving trastuzumab and/or lapatinib., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/14633
Publicación Otros (Other)

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

  • Powles, Thomas
  • Kockx, Mark
  • Rodriguez-Vida, Alejo
  • Duran, Ignacio
  • Crabb, Simon-J
  • Van-Der-Heijden, Michiel-S
  • Szabados, Bernadett
  • Pous, Albert-Font
  • Gravis, Gwenaelle
  • Herranz, Urbano-Anido
  • Protheroe, Andrew
  • Ravaud, Alain
  • Maillet, Denis
  • Mendez, Maria-Jose
  • Suarez, Cristina
  • Linch, Mark
  • Prendergast, Aaron
  • van-Dam, Pieter-Jan
  • Stanoeva, Diana
  • Daelemans, Sofie
  • Mariathasan, Sanjeev
  • Tea, Joy-S
  • Mousa, Kelly
  • Banchereau, Romain
  • Castellano, Daniel
Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4-7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21-41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/22181
Publicación Otros (Other)

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

  • Argiles, Guillem
  • Mulet, Nuria
  • Valladares-Ayerbes, Manuel
  • Vieitez, Jose-M
  • Gravalos, Cristina
  • Garcia-Alfonso, Pilar
  • Santos, Cristina
  • Tobeña, Maria
  • Garcia-Paredes, Beatriz
  • Benavides, Manuel
  • Cano, Maria-T
  • Loupakis, Fotios
  • Rodriguez-Garrote, Mercedes
  • Rivera, Fernando
  • Goldberg, Richard-M
  • Cremolini, Chiara
  • Bennouna, Jaafar
  • Ciardiello, Fortunato
  • Tabernero, Josep-M
  • Aranda, Enrique
The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). The primary end-point was the percentage of patients with G3/G4 treatment-related adverse events (AEs) in each arm. There were 299 patients randomly assigned to arm A (n = 101), arm B (n = 99), or arm C (n = 99); 297 initiated treatments (arm A n = 100, arm B n = 98, arm C n = 99: population for safety analyses). G3/4 treatment-related AEs occurred in 60%, 55%, and 54% of patients in arms A, B, and C, respectively. The most common G3/4 AEs were hypertension (19, 12, and 20 patients), fatigue (20, 14, and 15 patients), hypokalemia (11, 7, and 10 patients), and hand-foot skin reaction (8, 7, and 3 patients). Median overall survival was 7.4 (IQR 4.0-13.7) months in arm A, 8.6 (IQR 3.8-13.4) in arm B, and 7.1 (IQR 4.4-12.4) in arm C. The alternative regorafenib dosing schedules were feasible and safe in patients with mCRC who had been previously treated with standard therapy. There was a higher numerical improvement on the most clinically relevant AEs in the intermittent dosing arm, particularly during the relevant first two cycles., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/12734
Publicación Otros (Other)

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

  • Martinez-Laperche, Carolina
  • Buces, Elena
  • Aguilera-Morillo, M-Carmen
  • Picornell, Antoni
  • Gonzalez-Rivera, Milagros
  • Lillo, Rosa
  • Santos, Nazly
  • Martin-Antonio, Beatriz
  • Guillem, Vicent
  • Nieto, Jose-B
  • Gonzalez, Marcos
  • Camara, Rafael-de-la
  • Brunet, Salut
  • Jimenez-Velasco, Antonio
  • Espigado, Ildefonso
  • Vallejo, Carlos
  • Sampol, Antonia
  • Bellon, Jose-Maria
  • Serrano, David
  • Kwon, Mi
  • Gayoso, Jorge
  • Balsalobre, Pascual
  • Urbano-Izpizua, Alvaro
  • Solano, Carlos
  • Gallardo, David
  • Diez-Martin, Jose-Luis
  • Romo, Juan
  • Buño, Ismael
Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disease (GVHD), its prediction remains unresolved and depends mainly on clinical data. The aim of this study is to build a predictive model based on clinical variables and cytokine gene polymorphism for predicting acute GVHD (aGVHD) and chronic GVHD (cGVHD) from the analysis of a large cohort of HLA-identical sibling donor allogeneic stem cell transplant (allo-SCT) patients. A total of 25 SNPs in 12 cytokine genes were evaluated in 509 patients. Data were analyzed using a linear regression model and the least absolute shrinkage and selection operator (LASSO). The statistical model was constructed by randomly selecting 85% of cases (training set), and the predictive ability was confirmed based on the remaining 15% of cases (test set). Models including clinical and genetic variables (CG-M) predicted severe aGVHD significantly better than models including only clinical variables (C-M) or only genetic variables (G-M). For grades 3-4 aGVHD, the correct classification rates (CCR1) were: 100% for CG-M, 88% for G-M, and 50% for C-M. On the other hand, CG-M and G-M predicted extensive cGVHD better than C-M (CCR1: 80% vs. 66.7%, respectively). A risk score was calculated based on LASSO multivariate analyses. It was able to correctly stratify patients who developed grades 3-4 aGVHD (P < .001) and extensive cGVHD (P < .001). The novel predictive models proposed here improve the prediction of severe GVHD after allo-SCT. This approach could facilitate personalized risk-adapted clinical management of patients undergoing allo-SCT., The authors would like to thank the Centro Nacional de Genotipado for help with genotyping. They would also like to acknowledge the patients who participated in this study, as well as the staff of the Hematology Department, Hospital General Universitario Gregorio Marañón (Madrid, Spain), who made the study possible. This study was partially supported by Ministry of Economy and Competitiveness ISCIII-FIS Grants PI08/1463, PI11/00708, PI14/01731, PI17/01880, and RD12/0036/0061 and cofinanced by the European Regional Development Fund from the European Commission, the “A way of making Europe” initiative, and grants from Fundación LAIR and Asociación Madrileña de Hematología y Hemoterapia, Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/11907
Publicación Otros (Other)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

  • Seymour, John-F
  • Döhner, Hartmut
  • Butrym, Aleksandra
  • Wierzbowska, Agnieszka
  • Selleslag, Dominik
  • Jang, Jun-Ho
  • Kumar, Rajat
  • Cavenagh, James
  • Schuh, Andre-C
  • Candoni, Anna
  • Recher, Christian
  • Sandhu, Irwindeep
  • Bernal-del-Castillo, Teresa
  • Al-Ali, Haifa-Kathrin
  • Falantes, Jose
  • Stone, Richard-M
  • Minden, Mark-D
  • Weaver, Jerry
  • Songer, Steve
  • Beach, C-L
  • Dombret, Herve
Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65-74 years or ≥75 years). The same analyses were used to compare azacitidine with low-dose cytarabine in patients who had been preselected to low-dose cytarabine before they were randomized to receive azacitidine or CCR (ie, low-dose cytarabine). Median overall survival was significantly prolonged with azacitidine (n = 129) versus CCR (n = 133): 8.9 versus 4.9 months (hazard ratio 0.74, [95%CI 0.57, 0.97]). Among patients with intermediate-risk cytogenetics, median overall survival with azacitidine was 16.4 months, and with CCR was 8.9 months (hazard ratio 0.73 [95%CI 0.48, 1.10]). Median overall survival was significantly improved for patients ages 65-74 years treated with azacitidine compared with those who received CCR (14.2 versus 7.3 months, respectively; hazard ratio 0.64 [95%CI 0.42, 0.97]). Within the subgroup of patients preselected to low-dose cytarabine before randomization, median overall survival with azacitidine was 9.5 months versus 4.6 months with low-dose cytarabine (hazard ratio 0.77 [95%CI 0.55, 1.09]). Within the low-dose cytarabine preselection group, patients with intermediate-risk cytogenetics who received azacitidine had a median overall survival of 14.1 months versus 6.4 months with low-dose cytarabine, and patients aged 65-74 years had median survival of 14.9 months versus 5.2 months, respectively. Overall response rates were similar with azacitidine and CCR (24.8% and 17.3%, respectively), but higher with azacitidine versus low-dose cytarabine (27.2% and 13.9%). Adverse events were generally comparable between the treatment arms. Azacitidine may be the preferred treatment for patients with AML-MRC who are not candidates for intensive chemotherapy, particularly patients ages 65-74 years and those with intermediate-risk cytogenetics., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/29275
Publicación Otros (Other)

Comparación de la calidad de vida en personas que viven con infección por VIH en seguimiento mediante atención farmacéutica según metodología capacidad motivación-oportunidad vs. seguimiento convencional. Proyecto MAS-VIH.

Comparison of quality of life in patients living with HIV infection through pharmaceutical care according to CMO methodology vs. conventional follow-up. MAS-VIH project
  • Martinez-Sesmero, J-M
  • Margusino-Framiñan, L
  • Gimeno-Gracia, M
  • Areas-del-Aguila, V
  • Navarro-Aznares, H
  • Huertas-Fernandez, M-J
  • Molina-Cuadrado, E
  • Diaz-Ruiz, P
  • Martin-Conde, M-T
  • Alonso-Grandes, E
  • Lazaro-Lopez, A
  • Morillo-Verdugo, R
Comparar la calidad de vida en personas que viven con infección por el Virus de la Inmunodeficiencia Humana según el modelo de Atención Farmacéutica que reciben en los Servicios de Farmacia Hospitalaria: CMO (capacidad, motivación y oportunidad), versus seguimiento convencional. Método. Estudio longitudinal, prospectivo, multicéntrico, realizado entre octubre de 2019 y noviembre de 2021 en 14 Servicios de Farmacia Hospitalaria de España. Se incluyeron pacientes mayores de 18 años, que recibían tratamiento antirretroviral y acudían a las consultas de Atención Farmacéutica durante ≥1 año, excluyéndose aquellos sin autonomía para completar los cuestionarios previstos. Los centros fueron aleatorizados a seguir utilizando la misma sistemática de trabajo (seguimiento tradicional) o implementar el modelo CMO, utilizando la estratificación, el establecimiento de objetivos farmacoterapéuticos, el uso de entrevista motivacional y el seguimiento longitudinal con nuevas tecnologías. La variable principal fue la diferencia en el número de dimensiones afectadas negativamente, en cada rama, a las 24 semanas, según el cuestionario MOS-HIV. En el brazo CMO se registraron las intervenciones más frecuentemente realizadas. Resultados. Se incluyeron 151 pacientes, con una mediana de edad de 51,3 años. Se encontró una mejora significativa de la calidad de vida al final del seguimiento en el grupo CMO, reduciéndose el número de pacientes con dimensiones afectadas negativamente (2/11 vs 8/11). Las intervenciones más frecuentes llevadas a cabo, según la taxonomía, fueron motivación (51,7%) y revisión y validación del tratamiento antirretroviral (49,4%). Conclusiones. La calidad de vida de los pacientes es superior en aquellos centros que desarrollan Atención Farmacéutica basada en la metodología CMO en comparación con el seguimiento tradicional., To compare quality of life, in patients living with HIV infection with pharmaceutical care according to the CMO methodology: capacity, motivation and opportunity versus conventional follow-up. Longitudinal, prospective, multicenter, health intervention study, conducted between October 2019 and November 2021 in 14 centers throughout Spain. Patients over 18 years of age, receiving antiretroviral treatment and attending the consultations of the participating Pharmacy Services for 1 year were included. Patients who did not have the autonomy to complete the planned questionnaires were excluded. At baseline, participating centers were randomized to continue using the same systematics of work (traditional follow-up) or to implement the CMO model using patient stratification models, goal setting in relation to pharmacotherapy, use of motivational interviewing, as well as longitudinal follow-up enabled by new technologies. The main variable was the difference in the number of dimensions positively affected in each follow-up arm at 24 weeks of follow-up according to the MOS-HIV questionnaire. In the CMO group, the interventions performed the most frequently were recorded. 151 patients were included. The median age was 51.35 years. A significant improvement in quality of life was found at the end of follow-up in the CMO group, reducing the number of patients with negatively affected dimensions (2/11 vs 8/11). The most frequent interventions carried out in the CMO group, according to the taxonomy, were Motivation (51,7%) and review and validation (49,4%). The quality of life of patients is higher in those centers that develop Pharmaceutical Care based on the CMO methodology compared to traditional follow-up., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/15425
Publicación Otros (Other)

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

  • Balana, Carmen
  • Vaz, Maria-Angeles
  • Manuel-Sepulveda, Juan
  • Mesia, Carlos
  • Barco, Sonia-del
  • Pineda, Estela
  • Muñoz-Langa, Jose
  • Estival, Anna
  • Peñas, Ramon-de-las
  • Fuster, Jose
  • Girones, Regina
  • Navarro, Luis-Miguel
  • Gil-Gil, Miguel
  • Alonso, Miriam
  • Herrero, Ana
  • Peralta, Sergio
  • Olier, Clara
  • Perez-Segura, Pedro
  • Covela, Maria
  • Martinez-Garcia, Maria
  • Berrocal, Alfonso
  • Gallego, Oscar
  • Luque, Raquel
  • Perez-Martin, Franciso-Javier
  • Esteve, Anna
  • Munne, Nuria
  • Domenech, Marta
  • Villa, Salvador
  • Sanz, Carolina
  • Carrato, Cristina
Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized trial investigating whether extending adjuvant temozolomide for more than 6 cycles improved outcome. Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after 6 cycles of adjuvant temozolomide were centrally randomized to stop (control arm) or continue (experimental arm) temozolomide up to a total of 12 cycles at the same doses they were receiving in cycle 6. Patients were stratified by MGMT methylation and measurable disease. The primary endpoint was differences in 6-month progression-free survival (PFS). Secondary endpoints were PFS, overall survival (OS), and safety (Clinicaltrials.gov NCT02209948). From August 2014 to November 2018, 166 patients were screened, 7 of whom were ineligible. Seventy-nine patients were included in the stop arm and 80 in the experimental arm. All patients were included in the analyses of outcomes and of safety. There were no differences in 6-month PFS (control 55.7%; experimental 61.3%), PFS, or OS between arms. MGMT methylation and absence of measurable disease were independent factors of better outcome. Patients in the experimental arm had more lymphopenia (P  Continuing temozolomide after 6 adjuvant cycles is associated with greater toxicity but confers no additional benefit in 6-month PFS. 1. Extending adjuvant temozolomide to 12 cycles did not improve 6-month PFS.2. Extending adjuvant temozolomide did not improve PFS or OS in any patient subset.3. Extending adjuvant temozolomide was linked to increased toxicities., Si
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/31729
Publicación Otros (Other)

Endoscopic intragastric injection of botulinum toxin A in obese patients on bariatric surgery waiting lists: A randomised double-blind study (IntraTox study)

  • Francisco Jose Sanchez Torralvo
  • Luis Vazquez Pedreño
  • Montserrat Gonzalo Marin
  • Maria Jose Tapia
  • Fuensanta Lima
  • Eduardo Garcia Fuentes
  • Pilar Garcia
  • Javier Moreno Ruiz
  • Alberto Rodriguez Cañete
  • Sergio Valdes
  • Olveira, Gabriel
Several studies have evaluated the effect of intragastric injection of botulinum toxin A to treat obesity, achieving mixed results. Our objective is to determine the effect of intragastric botulinum toxin A on weight loss, satiety, biomarkers, and quality of life of obese patients prior bariatric surgery. Methods: Design: single-centre, randomised, double-blind, placebo-controlled clinical trial in 52 obese patients on bariatric surgery waiting lists. Two-arm parallel: the treatment group was administered intragastric botulinum toxin A by endoscopy, whereas the control group was administered physiological saline solution. Weight loss was evaluated at weeks 2, 4, 8, 16, and 24, as well as changes in body composition, satiety (Visual analogue scale (VAS) and GCSI questionnaire), quality of life (GIQLI questionnaire), and biomarkers of satiety and appetite. Results: Weight loss at weeks 2, 4, 8, 16, and 24 after the endoscopy, with respect to the basal visit, was 0.6 ± 2 kg, 0.4 ± 2.7 kg, 0.4 ± 3.1 kg, 0.2 ± 4.5 kg, and 0.6 ± 4.3 kg for the control group vs 1.9 ± 2.1 kg, 2 ± 2.6 kg, 2.8 ± 4.1 kg, 3.5 ± 5.3 kg, and 4.5 ± 7 kg for the treatment group, respectively, being differences between groups significant at all times (p = 0.016, 0.031, 0.014, 0.021, and 0.023, respectively). Treatment group patients obtained a significantly higher score for GIQLI questionnaire compared with baseline (104.4 ± 13.9 points vs 97.7 ± 15.6 points; p = 0.024), showing a significant improvement in the section of subjective physical capacity. No significant differences were found regarding perception of satiety, or biomarkers of satiety and appetite. Conclusions: Intragastric injection of botulinum toxin A is an effective and safe procedure to achieve a moderate weight loss and improve quality of life., Yes
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
oai:repositoriosalud.es:10668/20202
Publicación Otros (Other)

Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial.

  • Law, Zhe-Kang
  • Appleton, Jason-P
  • Scutt, Polly
  • Roberts, Ian
  • Al-Shahi-Salman, Rustam
  • England, Timothy-J
  • Werring, David-J
  • Robinson, Thompson
  • Krishnan, Kailash
  • Dineen, Robert-A
  • Laska, Ann-Charlotte
  • Lyrer, Philippe-A
  • Egea-Guerrero, Juan-Jose
  • Karlinski, Michal
  • Christensen, Hanne
  • Roffe, Christine
  • Bereczki, Daniel
  • Ozturk, Serefnur
  • Thanabalan, Jegan
  • Collins, Ronan
  • Beridze, Maia
  • Ciccone, Alfonso
  • Duley, Lelia
  • Shone, Angela
  • Bath, Philip-M
  • Sprigg, Nikola
Seeking consent rapidly in acute stroke trials is crucial as interventions are time sensitive. We explored the association between consent pathways and time to enrollment in the TICH-2 (Tranexamic Acid in Intracerebral Haemorrhage-2) randomized controlled trial. Consent was provided by patients or by a relative or an independent doctor in incapacitated patients, using a 1-stage (full written consent) or 2-stage (initial brief consent followed by full written consent post-randomization) approach. The computed tomography-to-randomization time according to consent pathways was compared using the Kruskal-Wallis test. Multivariable logistic regression was performed to identify variables associated with onset-to-randomization time of ≤3 hours. Of 2325 patients, 817 (35%) gave self-consent using 1-stage (557; 68%) or 2-stage consent (260; 32%). For 1507 (65%), consent was provided by a relative (1 stage, 996 [66%]; 2 stage, 323 [21%]) or a doctor (all 2-stage, 188 [12%]). One patient did not record prerandomization consent, with written consent obtained subsequently. The median (interquartile range) computed tomography-to-randomization time was 55 (38-93) minutes for doctor consent, 55 (37-95) minutes for 2-stage patient, 69 (43-110) minutes for 2-stage relative, 75 (48-124) minutes for 1-stage patient, and 90 (56-155) minutes for 1-stage relative consents (P The use of initial brief consent was associated with shorter times to enrollment, while maintaining good participant retention. Seeking written consent from relatives was associated with significant delays. URL: https://www.isrctn.com; Unique identifier: ISRCTN93732214., Si
Buscador avanzado